Covered recipient · General Payments record
HARPAUL S GILL
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$3,557.57
250 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,452.25 | 244 |
| Education | $72.38 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32.94 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 4 of 5; records 151–200 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HARPAUL S GILL
NPI 1023158409 · CMS profile ID 136717
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
CYPRESS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023158409?year=2021&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023158409?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023158409?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1023158409?year=2021&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
250 matching records · $3,557.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 250.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Avanir Pharmaceuticals, Inc. | $11.28 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801031873 | CMS |
| Biogen, Inc. | $23.17 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827836465 | CMS |
| Amneal Pharmaceuticals LLC | $5.47 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829656669 | CMS |
| Neurocrine Biosciences, Inc. | $14.32 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837792373 | CMS |
| Biohaven Pharmaceuticals, Inc. | $15.35 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852498789 | CMS |
| AbbVie Inc. | $22.56 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594657 | CMS |
| AbbVie Inc. | $14.46 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594653 | CMS |
| Biohaven Pharmaceuticals, Inc. | $9.88 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852498787 | CMS |
| UCB, Inc. | $28.62 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807358481 | CMS |
| Celgene Corporation | $18.63 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783706173 | CMS |
| Novartis Pharmaceuticals Corporation | $3.81 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692441 | CMS |
| Neurocrine Biosciences, Inc. | $5.19 | 05/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837792371 | CMS |
| AbbVie Inc. | $5.36 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594649 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.38 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845596707 | CMS |
| ACADIA Pharmaceuticals Inc | $23.10 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837999377 | CMS |
| Novartis Pharmaceuticals Corporation | $9.08 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692443 | CMS |
| Novartis Pharmaceuticals Corporation | $4.14 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692447 | CMS |
| AbbVie Inc. | $14.92 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594645 | CMS |
| Novartis Pharmaceuticals Corporation | $13.26 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692439 | CMS |
| AbbVie Inc. | $12.26 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594635 | CMS |
| AbbVie Inc. | $24.74 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594639 | CMS |
| ACADIA Pharmaceuticals Inc | $16.80 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837999373 | CMS |
| AbbVie Inc. | $5.10 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594631 | CMS |
| Biogen, Inc. | $16.93 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827836467 | CMS |
| AbbVie Inc. | $6.96 | 04/26/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594627 | CMS |
| Amneal Pharmaceuticals LLC | $11.47 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829656665 | CMS |
| BANNER LIFE SCIENCES, LLC | $16.45 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843736931 | CMS |
| Neurocrine Biosciences, Inc. | $5.11 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837792367 | CMS |
| Biohaven Pharmaceuticals, Inc. | $5.31 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852498785 | CMS |
| GE HEALTHCARE | $24.17 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837877611 | CMS |
| Adamas Pharmaceuticals, Inc. | $22.42 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834398081 | CMS |
| SK Life Science, Inc. | $16.54 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826822389 | CMS |
| AbbVie Inc. | $11.46 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594623 | CMS |
| UCB, Inc. | $24.02 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807351401 | CMS |
| Neurelis, Inc. | $33.83 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842865397 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.68 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834352225 | CMS |
| AbbVie Inc. | $13.14 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594615 | CMS |
| AbbVie Inc. | $1.97 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594619 | CMS |
| AbbVie Inc. | $16.42 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594611 | CMS |
| GENZYME CORPORATION | $22.66 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843599191 | CMS |
| ACADIA Pharmaceuticals Inc | $8.22 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837999369 | CMS |
| Neurocrine Biosciences, Inc. | $12.63 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837792365 | CMS |
| ACADIA Pharmaceuticals Inc | $13.66 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837999367 | CMS |
| AbbVie Inc. | $4.66 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594607 | CMS |
| Novartis Pharmaceuticals Corporation | $19.99 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692437 | CMS |
| Endo Pharmaceuticals Inc. | $17.01 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828723637 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $18.15 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828334353 | CMS |
| Currax Pharmaceuticals LLC | $12.02 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792529463 | CMS |
| AbbVie Inc. | $7.43 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794594603 | CMS |
| Novartis Pharmaceuticals Corporation | $11.79 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812692429 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $698,918.84 | 94 |
| PY2024 | Recipient | $9,000.00 | 2 |
| PY2024 | Principal investigator | $302,347.85 | 22 |
| PY2023 | Recipient | $86,476.00 | 12 |
| PY2023 | Principal investigator | $10,718.67 | 3 |
| PY2022 | Principal investigator | $20,313.44 | 5 |
| PY2021 | Principal investigator | $129,886.53 | 9 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
94 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $2,256.72 | 12/31/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease | No dispute reported | 06/30/2026 | 1202532390 |
| Principal investigator 1 | ARGENX US, INC. | $14,735.25 | 12/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237150741 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 12/05/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinsons Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202529270 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,257.00 | 12/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | ITI-1284-201 | No dispute reported | 06/30/2026 | 1242368311 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,777.00 | 12/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | ITI-1284-201 | No dispute reported | 06/30/2026 | 1242368313 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,065.00 | 12/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | ITI-1284-201 | No dispute reported | 06/30/2026 | 1242368315 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $483.00 | 12/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | ITI-1284-201 | No dispute reported | 06/30/2026 | 1242368317 |
| Principal investigator 1 | ABBVIE INC. | $1,984.50 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202524690 |
| Principal investigator 1 | ABBVIE INC. | $3,645.00 | 11/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202524696 |
| Principal investigator 1 | ABBVIE INC. | $6,496.90 | 11/07/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202523589 |
| Principal investigator 1 | ABBVIE INC. | $9,734.16 | 11/05/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202523149 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,415.00 | 11/03/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | ITI-1284-201 | No dispute reported | 06/30/2026 | 1242365197 |
| Principal investigator 1 | ABBVIE INC. | $307.80 | 10/09/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202516481 |
| Principal investigator 1 | ABBVIE INC. | $307.80 | 09/11/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202510804 |
| Principal investigator 1 | Celgene Corporation | $26,200.00 | 09/03/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1222306665 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,497.76 | 08/26/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1235996829 |
| Principal investigator 1 | ABBVIE INC. | $2,968.99 | 08/13/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202504495 |
| Principal investigator 1 | ABBVIE INC. | $7,887.15 | 08/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202503603 |
| Principal investigator 1 | ARGENX US, INC. | $1,800.00 | 08/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237150734 |
| Principal investigator 1 | ARGENX US, INC. | $2,750.00 | 08/01/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237150738 |
| Principal investigator 1 | ABBVIE INC. | $715.00 | 07/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202499152 |
| Principal investigator 1 | ABBVIE INC. | $307.80 | 07/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202499154 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,834.08 | 07/10/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111448 |
| Principal investigator 1 | ABBVIE INC. | $3,276.79 | 06/19/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202492451 |
| Principal investigator 1 | ARGENX US, INC. | $21,000.00 | 06/18/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237150730 |
| Principal investigator 1 | ABBVIE INC. | $14,947.21 | 06/17/2025 | Non-covered Recipient Entity GILL NEUROSCIENCE | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202491797 |
| Principal investigator 1 | ABBVIE INC. | $10,000.00 | 06/13/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202491505 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 06/05/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202490601 |
| Principal investigator 1 | ABBVIE INC. | $1,080.00 | 06/05/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202490603 |
| Principal investigator 1 | ABBVIE INC. | $1,515.00 | 06/05/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202490605 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,511.00 | 06/04/2025 | Non-covered Recipient Entity Northside Hospital Gwinnett | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | No dispute reported | 06/30/2026 | 1235995269 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $102.75 | 05/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169560 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $308.25 | 05/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170861 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $308.25 | 05/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170866 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $205.50 | 05/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170889 |
| Principal investigator 1 | ABBVIE INC. | $121.50 | 05/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202486011 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 05/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202486013 |
| Principal investigator 1 | ABBVIE INC. | $2,032.76 | 05/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202486015 |
| Principal investigator 1 | ABBVIE INC. | $135.00 | 05/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202486017 |
| Principal investigator 1 | ABBVIE INC. | $324.00 | 05/22/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202486019 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $438.40 | 05/14/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192119287 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $137.00 | 05/14/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192171985 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $986.40 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111418 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,386.54 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111424 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,263.14 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117130 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,233.00 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117161 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,549.77 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192119270 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,789.42 | 05/12/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192172008 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $161,155.25 | 05/09/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1235996833 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 05/08/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202484565 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,137.12 | 05/08/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1235996827 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $123.30 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111402 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,315.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111410 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,109.70 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111430 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,315.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111436 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $863.10 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192111441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $348.20 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117123 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $174.10 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117136 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,466.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117142 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,110.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117150 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $123.30 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117156 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $739.80 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117167 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,699.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192117174 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,055.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192119282 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $616.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169545 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $616.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169549 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,370.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169565 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $616.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170875 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $369.90 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170895 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,466.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192171998 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,740.00 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192172003 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,014.50 | 04/29/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192172012 |
| Principal investigator 1 | ABBVIE INC. | $4,750.00 | 04/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202479418 |
| Principal investigator 1 | ABBVIE INC. | $2,968.99 | 04/17/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202477809 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,397.50 | 03/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192171989 |
| Principal investigator 1 | ABBVIE INC. | $2,802.26 | 03/13/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202463818 |
| Principal investigator 1 | ABBVIE INC. | $10,022.73 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202459001 |
| Principal investigator 1 | ABBVIE INC. | $13,338.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459006 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459023 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459028 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459051 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459055 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 03/06/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) | No dispute reported | 06/30/2026 | 1202459058 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,243.38 | 02/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192119276 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,644.00 | 02/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170884 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,137.50 | 02/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192171980 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,055.00 | 02/26/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192171994 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,397.50 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192119264 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,184.21 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169552 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $616.50 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192169557 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,233.00 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170870 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,233.00 | 02/24/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192170880 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $131,516.50 | 02/03/2025 | Non-covered Recipient Entity Horizon Clinical Research Group | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1235996831 |
| Principal investigator 1 | ABBVIE INC. | $91,756.41 | 01/16/2025 | Non-covered Recipient Entity HORIZON CLINICAL RESEARCH GROUP | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202439785 |